Korea Prime Pharm Overview
- Founded
-
1995
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Korea Prime Pharm General Information
Description
Manufacturer of pharmaceutical drugs. The company develops chemical and biopharmaceutical drugs, enabling patients to get cure with their latest technology drugs.
Contact Information
Website
www.koreaprime.co.kr
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Primary Office
- Gwangju Jungangro 211 (Daeindong, interpersonal building)
- 7th floor, 8th floor, 9th floor (R 501-811)
- Dong-gu, 501-811
- South Korea
+82 000-000-0000
Korea Prime Pharm Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | Completed | Startup | ||||
| 1. Early Stage VC | Completed | Startup |
Korea Prime Pharm Patents
Korea Prime Pharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-6966644-B2 | A solid dispersion of dutasteride, a method for producing the same, and a pharmaceutical composition containing the same. | Active | 21-Nov-2017 | 000000000 | |
| JP-2021501195-A | A solid dispersion of dutasteride, a method for producing the same, and a pharmaceutical composition containing the same. | Active | 21-Nov-2017 | 000000000 | |
| US-20200306266-A1 | Solid dispersion of dutasteride, method for producing same, and pharmaceutical composition comprising same | Active | 21-Nov-2017 | 000000000 | |
| US-11324760-B2 | Solid dispersion of dutasteride, method for preparing the solid dispersion, and pharmaceutical composition including the solid dispersion | Active | 21-Nov-2017 | 000000000 | 0 |
| EP-3689368-A4 | Botulinum toxin composition having prolonged efficacy duration | Inactive | 29-Sep-2017 | C12Y304/24069 |
Korea Prime Pharm Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Kim Dae Ik | Chief Executive Officer & President | ||
| Byung-yong Hyon | President |